Patient-related outcomes with the use of checkpoint inhibitors for the treatment of metastatic non-small cell lung cancer

Lung cancer is the leading cause of cancer mortality worldwide and non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancers (1,2). The prognosis for patients with metastatic or stage IV NSCLC is extremely poor with five-year survival rates of less than 5% (3).